SKIN

$1.17

Pre-MarketAs of Mar 17, 8:00 PM UTC

The Beauty Health Company, a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America.

Recent News

Zacks
Mar 17, 2026

Don't Overlook Beauty Health (SKIN) International Revenue Trends While Assessing the Stock

Evaluate Beauty Health's (SKIN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Mar 13, 2026

The Beauty Health Company Q4 2025 Earnings Call Summary

Moby summary of The Beauty Health Company's Q4 2025 earnings call

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 13, 2026

The Beauty Health Co (SKIN) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges ...

Despite a slight dip in total revenue, The Beauty Health Co (SKIN) focuses on consumables growth and innovation to drive future success.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 13, 2026

Beauty Health Q4 Earnings Call Highlights

Beauty Health (NASDAQ:SKIN) executives emphasized progress on profitability and operational discipline during the company’s fourth-quarter 2025 earnings call, while outlining a strategy shift designed to drive longer-term growth by increasing utilization across its installed base rather than relying

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 12, 2026

Beauty Health (SKIN) Q4 2025 Earnings Transcript

Joining me on the call today is The Beauty Health Company's Chief Executive Officer, Pedro Malha, along with our Chief Financial Officer, Michael Monahan. But before discussing the progress we are making, I think it will be useful to step back a little and look at the broader market.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.